Veracyte swings to $25.5M profit on 15.5% revenue growth, TrueMRD launch

Filed July 31, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read

Key Changes

• high

  Total revenue rose 15.5% to $150.3M, driven by a 19% increase in testing revenue, while biopharmaceutical revenue fell 81% after the Veracyte SAS restructuring.

  MD&A: Revenue verify on EDGAR →
• high

  Cash and short-term investments grew $164.5M year-over-year to $485.2M, with six-month operating cash flow more than doubling to $72.3M.

  MD&A: Liquidity verify on EDGAR →
• high

  Patent litigation with Sonic Healthcare USA advanced: motion to dismiss denied, claim construction held, and an ex parte reexamination granted; trial now expected in Q1 next year.

  Notes: Litigation verify on EDGAR →